Literature DB >> 29493134

[Research advances on astragaloside-IV in treatment of diabetes mellitus and its complications pharmacological effects].

Liang-Zhen You1, Yi-Xuan Lin1, Zhao-Hui Fang2, Guo-Ming Shen1, Jin-Dong Zhao2, Ting-Ting Wang1.   

Abstract

Diabetes has become a global public health problem that seriously threatens human health. Traditional Chinese medicine, the characteristics of the role of multiple targets, has a unique advantage in the prevention and treatment of diabetes mellitus and its complications. Astragaloside-Ⅳ (AS-Ⅳ), one of the main activities of Astragalus membranaceus, has a series of pharmacological effects including improvement in the function of endothelial cells and neovascularization, anti-inflammatory, antioxidant, regulating energy metabolism, protectionnervous, anti-cancer and so on. In this paper, AS-Ⅳ to prevent and treat diabetes and its complications has been reviewed, which has effect on lowering blood sugar, lowering blood pressure, improving insulin resistance, inhibiting inflammatory reaction and oxidative stress. Additionally, it also can improve the diabetic animal and cell model of diabetic vascular disease, diabetic nephropathy, diabetic retinopathy, diabetic peripheral neuropathy, diabetic cardiomyopathy and other pathological damages. AS-Ⅳ may be a potential active substance for the treatment of diabetes and its complications. Copyright© by the Chinese Pharmaceutical Association.

Entities:  

Keywords:  astragaloside-Ⅳ ; diabetes ; new drugs ; pharmacological effects

Mesh:

Substances:

Year:  2017        PMID: 29493134     DOI: 10.19540/j.cnki.cjcmm.20171010.007

Source DB:  PubMed          Journal:  Zhongguo Zhong Yao Za Zhi        ISSN: 1001-5302


  7 in total

1.  Astragalus Polysaccharides/PVA Nanofiber Membranes Containing Astragaloside IV-Loaded Liposomes and Their Potential Use for Wound Healing.

Authors:  Yuan Yue; Xinjun Liu; Lan Pang; Yue Liu; Yuzhu Lin; Ting Xiang; Jie Li; Shiqin Liao; Yunlan Jiang
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-11       Impact factor: 2.650

2.  HPLC-MS and Network Pharmacology Analysis to Reveal Quality Markers of Huo-Xue-Jiang-Tang Yin, a Chinese Herbal Medicine for Type 2 Diabetes Mellitus.

Authors:  Qiugu Chen; Yuan Zhao; Maosheng Li; Ping Zheng; Shangbin Zhang; Huilin Li; Jianping Chen
Journal:  Evid Based Complement Alternat Med       Date:  2021-03-15       Impact factor: 2.629

3.  Xiaoketongbi Formula vs pregabalin for painful diabetic neuropathy: A single-center, randomized, single-blind, double-dummy, and parallel controlled clinical trial.

Authors:  Qiyun Lu; Benjian Chen; Qingshun Liang; Liyan Wu; Lulu Luo; Anxiang Li; Wenwei Ouyang; Zehuai Wen; Yunwei Liu; Jiayan Lu; Yunyi Liu; Guanjie Fan; Zhenjie Liu
Journal:  J Diabetes       Date:  2022-08       Impact factor: 4.530

4.  An Ethnopharmaceutical Study on the Hypolipidemic Formulae in Taiwan Issued by Traditional Chinese Medicine Pharmacies.

Authors:  Min-Han Chi; Jung Chao; Chien-Yu Ko; Shyh-Shyun Huang
Journal:  Front Pharmacol       Date:  2022-09-15       Impact factor: 5.988

5.  Neuroprotective effect of diosgenin in a mouse model of diabetic peripheral neuropathy involves the Nrf2/HO-1 pathway.

Authors:  Jinhong Leng; Xiaohua Li; He Tian; Chang Liu; Yining Guo; Su Zhang; Yang Chu; Jian Li; Ying Wang; Ling Zhang
Journal:  BMC Complement Med Ther       Date:  2020-04-26

6.  Efficacy of Chinese Herbal Medicine in the Treatment of Moderate-Severe Painful Diabetic Peripheral Neuropathy: A Retrospective Study.

Authors:  Yujiao Zheng; Fan Yang; Lin Han; Xiaowen Gou; Fengmei Lian; Wenke Liu; Linhua Zhao; Bing Pang; Xiyan Zhao; Xiaolin Tong
Journal:  J Diabetes Res       Date:  2019-12-23       Impact factor: 4.011

7.  Integrated metabolomics and transcriptomics study of traditional herb Astragalus membranaceus Bge. var. mongolicus (Bge.) Hsiao reveals global metabolic profile and novel phytochemical ingredients.

Authors:  Xueting Wu; Xuetong Li; Wei Wang; Yuanhong Shan; Cuiting Wang; Mulan Zhu; Qiong La; Yang Zhong; Ye Xu; Peng Nan; Xuan Li
Journal:  BMC Genomics       Date:  2020-11-18       Impact factor: 3.969

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.